Skip to content

Advanced Electrotherapy In Diabetes Mellitus Type 2

Effects of Pulsed Electromagnetic Field Therapy in Individuals with Diabetes Mellitus Type 2 : A Randomised Controlled Trial - P.E.M.F. in DM 2

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025584
Enrollment
100
Registered
2020-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Pulsed Electromagnetic Field Therapy and Exercise Therapy: Pulsed Electromagnetic Field Therapy for 12 weeks along with exercise therapy- Group 1 P.E.M.F. therapy for 30 minutes daily f

Sponsors

Nigel Gonsalves
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals diagnosed with Diabetes Mellitus Type 2 for more than 6 months (Fasting Plasma Glucose > 126 mg/dL 6.5% Individuals on Normal Blood Glucose concentration lowering medications

Exclusion criteria

Exclusion criteria: 1. Individuals having a difficulty in attaining sitting position for 30 minutes. 2. Suffering from acute fractures in the spinal region. 3. Individuals with musculoskeletal disorders like strains, sprains, fractures causing an impairment to perform physical activity. 4. Suffering from cardio - vascular disorders. 5. Suffering from neurological disorders. 6. Individuals with diabetes mellitus type 2 suffering from foot ulcers. 7. Individuals undergoing any other form of exercise training. 8. Individuals who are hypoglycemic. 9. Individuals who are handicapped. 10. Pregnant females. 11. Individuals who are suffering from cancer. 12. Individuals who are having sensory impairment. 13. Individuals suffering from kidney dysfunction or disorders. 14. Individuals with pacemaker. 15. Individuals with implants of gel or silicon and / or transplant organs.

Design outcomes

Primary

MeasureTime frame
1. Fasting blood glucose 2. HbA1cTimepoint: At baseline, 4 weeks, 8 weeks, 12 weeks

Secondary

MeasureTime frame
1. Nitric oxide concentrationTimepoint: 1. Baseline 2. 12 weeks

Countries

India

Contacts

Public ContactTushar Palekar

Dr. D.Y. Patil Vidyapeeth, Pune - 18

principal.physio@dpu.edu.in9822606869

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026